Wang H, Wu J, Fang Y, Li Q
Int J Mol Sci. 2025; 26(5).
PMID: 40076530
PMC: 11899465.
DOI: 10.3390/ijms26051903.
He W, Zhao L, Wang P, Ren M, Han Y
BMC Biotechnol. 2025; 25(1):11.
PMID: 39856662
PMC: 11760099.
DOI: 10.1186/s12896-025-00944-y.
Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M
J Transl Med. 2025; 23(1):10.
PMID: 39755643
PMC: 11700462.
DOI: 10.1186/s12967-024-06052-3.
Croft M, Salek-Ardakani S, Ware C
Nat Rev Drug Discov. 2024; 23(12):939-961.
PMID: 39448880
DOI: 10.1038/s41573-024-01053-9.
Baran J, Kuryk L, Garofalo M, Pancer K, Wieczorek M, Kazek M
BioTechnologia (Pozn). 2024; 105(3):263-272.
PMID: 39439719
PMC: 11492889.
DOI: 10.5114/bta.2024.141805.
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.
Dobrin A, Lindenbergh P, Shi Y, Perica K, Xie H, Jain N
Nat Cancer. 2024; 5(5):760-773.
PMID: 38503896
DOI: 10.1038/s43018-024-00744-x.
TCR Signals Controlling Adaptive Immunity against Toxoplasma and Cancer.
Okamoto M, Yamamoto M
Adv Exp Med Biol. 2024; 1444:177-193.
PMID: 38467980
DOI: 10.1007/978-981-99-9781-7_12.
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.
Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G
Am J Clin Dermatol. 2024; 25(3):447-461.
PMID: 38236520
PMC: 11070399.
DOI: 10.1007/s40257-023-00838-9.
4-1BB immunotherapy: advances and hurdles.
Singh R, Kim Y, Lee S, Eom H, Choi B
Exp Mol Med. 2024; 56(1):32-39.
PMID: 38172595
PMC: 10834507.
DOI: 10.1038/s12276-023-01136-4.
Enhancing CAR-T cells: unleashing lasting impact potential with phytohemagglutinin activation in in vivo leukemia model.
Sert B, Gulden G, Teymur T, Ay Y, Turan R, Unaldi O
Cancer Gene Ther. 2023; 31(3):387-396.
PMID: 38092962
DOI: 10.1038/s41417-023-00709-9.
Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.
Izadi S, Gumpelmair S, Coelho P, Duarte H, Gomes J, Leitner J
Plant Biotechnol J. 2023; 22(5):1224-1237.
PMID: 38050338
PMC: 11022803.
DOI: 10.1111/pbi.14260.
Diagnostic Value of CD25, CD69, and CD134 on Tuberculosis-Specific Antigen-Stimulated CD4+ T Cells for Tuberculous Pleurisy.
Shi H, Yang L, Zhang F, Zhou Y, Zhou Y
J Immunol Res. 2023; 2023:5309816.
PMID: 37809012
PMC: 10551431.
DOI: 10.1155/2023/5309816.
Microbiota-dependent regulation of costimulatory and coinhibitory pathways via innate immune sensors and implications for immunotherapy.
Park J, Gazzaniga F, Kasper D, Sharpe A
Exp Mol Med. 2023; 55(9):1913-1921.
PMID: 37696895
PMC: 10545783.
DOI: 10.1038/s12276-023-01075-0.
Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects.
Cortellino S, Quagliariello V, Delfanti G, Blazevits O, Chiodoni C, Maurea N
Nat Commun. 2023; 14(1):5529.
PMID: 37684243
PMC: 10491752.
DOI: 10.1038/s41467-023-41066-3.
Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.
Salek-Ardakani S, Zajonc D, Croft M
Front Immunol. 2023; 14:1228486.
PMID: 37662949
PMC: 10469789.
DOI: 10.3389/fimmu.2023.1228486.
CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects.
Glez-Vaz J, Azpilikueta A, Ochoa M, Olivera I, Gomis G, Cirella A
Sci Adv. 2023; 9(33):eadf6692.
PMID: 37595047
PMC: 11044178.
DOI: 10.1126/sciadv.adf6692.
Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.
Redmond W
Expert Opin Biol Ther. 2023; 23(9):901-912.
PMID: 37587644
PMC: 10530613.
DOI: 10.1080/14712598.2023.2249396.
Therapeutic strategies to enhance immune response induced by multiple myeloma cells.
Liu Z, Yang C, Liu X, Xu X, Zhao X, Fu R
Front Immunol. 2023; 14:1169541.
PMID: 37275861
PMC: 10232766.
DOI: 10.3389/fimmu.2023.1169541.
Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins.
Pan S, Zhao W, Li Y, Ying Z, Luo Y, Wang Q
Front Immunol. 2023; 14:1189161.
PMID: 37256126
PMC: 10225568.
DOI: 10.3389/fimmu.2023.1189161.
Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice.
Matas-Cespedes A, Lapointe J, Elder M, Browne G, Dovedi S, de Haan L
Front Immunol. 2023; 14:1107848.
PMID: 36936963
PMC: 10020612.
DOI: 10.3389/fimmu.2023.1107848.